News >

Lower Dose ATLG Safer, More Effective in Children With Hematologic Malignancies

Jason Harris
Published: Thursday, Sep 14, 2017

mcl
A 15 mg/kg dose of rabbit anti-T-lymphocyte globulin (ATLG) was associated with similar graft-vs-host-disease (GVHD), less nonrelapse mortality, and less disease recurrence compared with a 30 mg/kg dose for children with hematological malignancies.

In the multivariable analysis of EFS, 30 mg/kg dose, HLA disparity of more than 1 allele, and high-risk disease were all associated with poorer outcome. Only the high-risk disease group was significantly associated with an increased risk for relapse, whereas the 30-mg/kg dose was associated with an increased risk for nonrelapse mortality.
Locatelli F, Bernardo ME, Bertaina A, et al. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(8):1126-1136. doi: 10.1016/S1470-2045(17)30417-5.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x